Combination therapy for the treatment of migraine
CA 2312633 A1 · Owner: Harrison, Wilma Marcia · Inventors: Harrison, Wilma Marcia; Sands, George Harry
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a pharmaceutical composition (or medicine) for treating migraine in a mammal including a human, which comprises (1) a 5HT1 receptor agonist (2) caffeine and, (3) a cyclooxygenase-2 (COX-2) inhibitor. The COX-2 inhibitor is a compound of the formula (I):, (see formula I) (wherein R1 is sulfamyl, R2 is haloalkyl R3 is hydrogen or, alkyl and R4 is aryl cycloalkyl or cycloalkenyl, each, optionally substituted) or a compound of the formula (II): (see formula II, (wherein R1 is alkyl, carboxyalkyl or the like R3 is, cycloalkyl, cycloalkenyl or aryl each optionally substituted, and R4 is alkyl hydroxyl or amino).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 28, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.